Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding

por Caroti, Kimberly Snow, Becattini, Cecilia, Carrier, Marc, Cohen, Alexander T., Ekbom, Anders, Khorana, Alok A., Lee, Agnes Y.Y., Brescia, Christopher, Abdelgawwad, Khaled, Psaroudakis, George, Rivera, Marcela, Schaefer, Bernhard, Brobert, Gunnar, Coleman, Craig I.
Publicado 2023

Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program

por Caroti, Kimberly Snow, Khorana, Alok A., Becattini, Cecilia, Lee, Agnes Y.Y., Ekbom, Anders, Carrier, Marc, Cohen, Alexander T., Brescia, Christopher, Abdelgawwad, Khaled, Psaroudakis, George, Rivera, Marcela, Schaefer, Bernhard, Brobert, Gunnar, Coleman, Craig I.
Publicado 2023

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism

por Coleman, Craig I., Caroti, Kimberly Snow, Abdelgawwad, Khaled, Psaroudakis, George, Fatoba, Samuel, Rivera, Marcela, Schaefer, Bernhard, Brobert, Gunnar, Khorana, Alok A., Becattini, Cecilia, Lee, Agnes Y.Y., Ekbom, Anders, Carrier, Marc, Brescia, Christopher, Cohen, Alexander T.
Publicado 2023